Tf1 survey european markets dependence on china and india for medicine supply

RSS

Login

Home Browse All

Press Release

Events

By Industry

By Subject

Resources

tw itter Fri, 16 Dec 2016 14:05

Register

RSS/Syndication

My Account

Tools

TF1 Survey - European Markets dependence on China and India for medicines supply

Printer Friendly Version

20 hours survey conducted by TF1 News France look ing at the European Mark ets dependence on China and India for Pharmaceuticals supply - Mis en ligne le & Vandana Malik

Subscribe to New s Feed

Recom m end

Share

Home

International

Brow se more on Âť Health Care/Hospitals, Economic new s, trends, analysis

Tweet

Contact

Maharashtra, Mumbai, February 6, 2012 /India PRwire/ --

For more information, please contact:

Europe is becoming increasingly dependent on a high

Network 18 pvt. Ltd. TF1 is a national French TV channel

Without the appropriate level of control and monitoring, this could easily lead to shortages and problems with supply continuity in those smaller markets. Globalisation of the generic must be met if the sector is not to be marginalised with respect to both pricing and supply. Innovation has been traditionally companies. However, generic medicine companies often spend

Mis en ligne le Reporter Email, (L) 01 76 47 10 30, (F) 01 76 47 10 60 Vandana Malik Executive Director Email, (L) +91-22-6666 7777, (F) +91-22-2496 8238

medicines industry will bring new challenges to Europe which

perceived as the domain of the research-based originator

Bookm ark for later Share it w ith others

0

percentage of imported generic medicines from India and China.

Dow nload as PDF

Shanatnu Kumar Singh - Chief Financial Officer of Taj Pharma Group - TF1 National French TV channel...

significant sums on innovating - improving formulations, enhancing delivery systems and finding solutions to patient compliance issues.

In an interview with an Indian CFO, Shantanu Kumar Singh, Taj Pharma Group, Mr. Singh commented, "A generic medicine treatment is now available within many of the major

Download Attachments Shanatnu Kumar Singh - Chief Financial Officer of Taj Pharma Group - TF1 - National French TV channel...

TF1 is a national French TV channel

therapeutic classes and this is often the 'gold standard' option for specific diseases. Opportunities exist to recommend schedules that encourage initiation of treatment with these 'gold standard' generic medicines. This is a positive sign which should increase the uptake of these drugs and potentially generate long-term savings through the use of a safe and effective therapy at an affordable Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Journalists and Bloggers Visit India PRwire for Journalists for releases, photos, email alerts and customized feeds just for Media.

price. " Singh also mentions, 'In 2011, 7% of revenues from the generics medicine industry were spent on research and development alone. Furthermore, sector investments in manufacturing and development facilities have created a solid base of employment (150,000 direct employees in the EU2) yielding societal benefits that go beyond the realms of healthcare. The potential benefits of the generics

If you have any query regarding information in the press releases, please contact the company listed in the press release itself. Please do not call India PRwire, we will be unable to assist you with your inquiry.

medicine industry will not be maximised if the focus is on the lowest price alone. There is a need to increase the volume of generic medicines penetration in the EU market and optimise such key areas as competition with in-patent medicines, co-payment policies, time to market, and ready supply'.

What do you think about the rising costs of health care in Europe?

Network 18 pvt. Ltd. recent press release(s)

The provision of an effective and efficient healthcare system in any country is a complex equation

Judgment of Novartis Glivec: Taj Pharma and Indian healthcare companies Gains in India The Indian Supreme Court rejected the appeal of the

balancing appropriate levels of patient care with resources available. Within this lies the need for

Novartis patent protection of the updated version

infrastructures to support both primary and secondary care as well as associated services such as

dell'antitumorale Glivec.

social welfare. Making direct comparisons of costs and best practices across EU member states is

FDA approval of generic version of cancer drug doxorubicin hydrochloride liposome injection is expected to help resolve shortage of drug supply FDA approved generic version of cancer drug

difficult; inherent political differences give rise to highly variable systems. No one country is the same. However, one element that is common to all and often the focus of attention is the cost of medicines. Although medicines generally constitute only around 10% of a country's total healthcare budget (with generic medicines only comprising between 1-2%) they are a prime target for cost savings - despite being arguably the most cost-effective part of the healthcare solution. However, even here, the lack of coherent policies and variations in pricing and reimbursement systems, sociodemographics and the management of healthcare within each EU member state make comparisons difficult. What works in one country may be totally inappropriate in another. One thing is certain, the ageing population and changes in lifestyle automatically bring an increased demand for healthcare and consequent escalation of costs. Pharmaceutical expenditure has been growing at comparable rates across all the major Western markets, with the developing markets exhibiting greater growth due to expanding access to medicines. Prolonged life expectancy in diseases previously associated with high mortality is also extending the use of longer-term chronic therapy treatments, further increasing the burden on healthcare providers. It is a fundamental principle in medicine that pharmaceuticals can delay or even prevent the need for costly hospitalisation in some patients. Therapies to improve quality of life in patients with terminal diseases are also playing a growing role in the physicians' armamentarium. Against this background, it is possible to draw a correlation between life expectancy and pharmaceutical consumption.

Pharmaceuticals undeniably play an essential role in improving and maintaining health, but managing and controlling cost remains a major challenge for society, including governments and Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

doxorubicin hydrochloride liposome which is used to treat patients with ovarian cancer and currently faced with shortage supply Aspirin cuts throat cancer risk: Study Aspirin, already known to stave off a host of diseases can also reduce the risk of throat cancer, anew study has claimed.

Economic slowdown of the third largest economy of the world, can 'India' realise the double digit growth rate?

Third largest economy losing credibility with the dipping GDP 4-6%, will government's 'damage control mode' bring back the required growth?

FDA Approves Drug To Reduce Risk Of HIV Infection by combining tenofovir disoproxil fumarate and emtricitabine The US Food and Drug Administration (FDA), announced on Monday that it has approved an existing drug, Truvada for reducing risk of infection

payers. Although the percentage of GDP spent on healthcare is fairly consistent in the major EU countries, the absolute amounts available are straining to deliver the desired levels of healthcare.

You're announcing strong first half results today. What's driven that performance?

Shantanu Kumar Singh, CFO (Taj Pharma Group) comments, 'I have to say I'm very, very happy, we're extremely pleased by the results that we announced today'. We're looking at revenues up by 22.6%, we're looking at our operating profits up by 40%, gross margins are almost 50%, fantastic cash flow growth by 74%, and we have a fantastic net debt to equity ratio of 18%. So we're very, very happy with these numbers. I've always said that this is a very well diversified business, and we have three main engines that continuously feed this growth. So this year for the first half, the US Generic business did extremely, extremely well, so we're very happy with that. That has been fantastic growth. Our Injectable business for the first half was very good also, we're very happy with that. And the Brand business, as we had previously said, would this year be split almost evenly between the first half and second half. So the Brand business was stable and we are looking at very good growth in the Brand business for the second half of the year. So overall, all three engines have been performing quite well, and the diversity and diversification has come in and worked again to give us these fantastic results....

Notes to Editor SEC Disclaimer This press release contains forward-look ing statements. The words or phrases "would be," "will allow," "intends to," "will lik ely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-look ing statements." Actual results could differ materially from those projected in Taj Pharma's ("the Company") business plan. The Company's business is subject to various risk s, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The interview given by Shantanu Kumar Singh CFO should not be construed as an indication in any way whatsoever of the value of the Company or its common stock . The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertak e, and we specifically disclaim any obligation, to update any forward-look ing statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

About TF1 TV channel France TF1 is a national French TV channel, controlled by TF1 Group, whose major share-holder is Bouygues. TF1's average market share of 24% makes it the most popular domestic network.

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

by sexually transmitted HIV-1 in adults.

Flagship shows include Star Academy (Endemol's international competitor to the X Factor franchise), CSI and House, M.D. TF1 originally stood for Télévision Française 1 (French Television 1).

Since its privatisation in 1987, the abbreviation is no longer expanded, so as to avoid confusion with the government-owned channel France Télévisions. The channel is part of the TF1 Group of mass media companies, which also includes the news channel LCI and Eurosport, the largest European sports network. Together with France Télévisions, TF1 co-managed the international French news channel France 24 but has since sold its share. TF1 is a supporter of the Hybrid Broadcast Broadband TV (HbbTV) initiative (a consortium of broadcasting and Internet industry companies including SES, OpenTV and Institut für Rundfunktechnik) that is promoting and establishing an open European standard for hybrid set-top boxes for the reception of broadcast TV and broadband multimedia applications with a single user interface.

Taj Pharmaceuticals Group Taj Pharmaceuticals Limited is known as a pharmaceuticals manufacturing company found and based in India. The company manufacturer's pharmaceuticals formulations and API for India and other countries. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Iran, Iraq and Asia Pacific. In recent EU-Indonesia Business Dialogue (EIBD) conference Taj Pharma Group was listed amongst top 10 pharmaceutical companies in EU by 2008 sales. The Group sales 16,234 ($M) making the company 12 ranked in EU by 2008 sales. Founded as a company for finished formulation marketing and Export and then entered Api and Agro business in 2004 and 2007 respectively.Taj Pharmaceuticals Limited announced the purchase of Mulberry chemicals (MulChem) wholly-owned US subsidiary from REVIB, Administration (DEA) as a narcotic raw material manufacturer. The founder of Taj Pharmaceuticals, Dr. R. K. Singh, is known as entrepreneur who was convinced that the future belonged to branded pharmaceutical products way back in 1995. Mr Singh is among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease. Dr. R. K. Singh attached great importance to product information as the link between the pharmaceutical manufacturer and doctors, pharmacists and patients. Shortly after the foundation of the company, affiliates were opened in Mauritius, Malaysia, Dubai, Moscow, England, France, the US, Great Britain and Russia.

PR Distribution | India Public Relations Firms & Agencies | PR Flash © Copyright 2016 India PRwire. All Rights Reserved.

India PRwire disclaims any content contained in press release. Use of our service is governed b y our Privacy Policy and Terms of Service.

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!